Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594832 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL18496512 | 0.80 | ALDH1A1 (0.71) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL4539658 | 0.77 | SMN1; SMN2 (1.00) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL29989707 | 0.77 | SMN1; SMN2 (1.00) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL23610616 | 0.76 | SMN1; SMN2 (0.67) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL4593656 | 0.76 | ALDH1A1 (0.65) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL27164742 | 0.75 | SMN1; SMN2 (0.74) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL14548000 | 0.75 | HRH4 (0.66) | ALDH1A1LMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL31110303 | 0.74 | SMN1; SMN2 (0.63) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 | |
| SCHEMBL24056130 | 0.74 | SMN1; SMN2 (0.63) | ALDH1A1LMNAKMT2AGPR55SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | ALDH1A1 1823/4885LMNA 4565/4885KMT2A 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.